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Objectives: To describe the therapeutic pathways of patients with psoriasis (PSO) and psoriatic 
arthritis (PsA) before and after treatment with biological therapies in a real-world setting and 
to determine the relative consumption of health care resources.
Design: Retrospective observational study.
Setting: Real-life clinical setting in 5 Italian local health units.
Participants: A total of 351 male and female patients with at least 1 prescription for a biologi-
cal drug from January 1, 2010 to December 31, 2013; patients with concomitant rheumatoid 
arthritis, ankylosing spondylitis, or Crohn’s disease were excluded.
Results: The major health care cost (excluding drug costs) was represented by hospitaliza-
tions, mainly related to PSO /PsA-associated disorders and cardiometabolic disorders. Use of 
conventional drugs among biologics-naïve patients reached 50% in PSO and 80% in PsA; their 
use decreased following initiation of biological therapy. After the start of biological treatment, 
the incidence of hospitalization decreased both for PSO (from 12.3% to 3.2% in day hospital 
regimen and from 2.4% to 0.4% for conventional admission) and for PsA (from 11.1% to 8.1% 
and from 10.1% to 3.0%, respectively). Mean annual costs for hospitalization before biologi-
cal treatment were €217 and €537 for PSO and PsA, respectively, while mean annual cost for 
concomitant drugs slightly increased after biologics initiation: from €249.8 to €269.4 for PSO 
and from €331.8 to €346.9 for PsA. The major consumption of health care resources occurred 
in the quarter preceding the beginning of biological treatment.
Conclusion: The consumption of health resources is mostly related to hospitalization, seems to 
peak during the quarter before the beginning of biologics therapies, and subsequently decreases 
after biologics initiation. Further studies should focus on prescription scheme and economic 
burden of PSO and PsA in Italy to help optimize health care resources and potentiate services 
for patients. 
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Introduction
Psoriasis (PSO) is a chronic inflammatory, immune-mediated, genetically based dis-
ease affecting the skin and joints with a significant impact on quality of life. PSO is 
observed in 0.9%–8.5% of world population.1 In addition, European epidemiological 
data confirm that about 2%–3% of Caucasian population is affected by this disorder.2,3 
In Italy, the prevalence of PSO is estimated around 2.8%, with higher rates in men 
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than women.4 Approximately 30% of patients with PSO (with 
a range from 6% to 42%) will develop psoriatic arthritis 
(PsA).5 PsA is a chronic inflammatory disease of the joints 
associated with cutaneous PSO or with a familial history of 
PSO.3 In the Italian population, the estimated prevalence of 
PsA is 0.42%.6 A prompt diagnosis (ideally within 12 months 
from initial symptoms) and adequate treatment of PsA may 
prevent/delay disease progression, avoiding permanent and 
irreversible bone damage.7
The selection of therapy in patients with PSO depends on 
disease severity, presence of PsA and/or other comorbidities 
or not, as well as patients characteristics and preferences.8 
Several therapeutic options are available for patients with 
PSO, including topical treatments, ultraviolet radiation, 
conventional systemic therapy (methotrexate, cyclosporine, 
acitretin), biological drugs targeting single proinflammatory 
cytokines (TNF-α, IL-12/23 and 17 inhibitors) and, only 
recently, the PDE4 inhibitor, apremilast.9 PsA treatment 
includes symptomatic drugs (nonsteroidal anti-inflamma-
tory drugs [NSAIDs], glucocorticoids, classical disease-
modifying antirheumatic drugs [DMARDs] [methotrexate, 
leflunomide, cyclosporine, sulfasalazine]), biological drugs 
(anti-TNF-α, anti-IL 12/23/17) and apremilast.8,10 According 
to the Italian Medicines Agency (AIFA) guidelines, biologi-
cal drugs can be prescribed and reimbursed by the National 
Health System (NHS) only after failure, contraindications, 
or intolerance to conventional systemic treatments.11
The main objective of the present work was to describe 
the therapeutic courses of patients with PSO and PsA before 
and after treatment with biological therapies in a real-world 
setting. The secondary aim of the study was to determine the 
consumption of health care resources in patients with PSO 
and PsA including drugs, diagnostic interventions, special 
medical examinations, and hospitalizations, in relation to the 
therapeutic strategy utilized.
Methods
Data sources
Patient data were retrieved from the administrative data-
bases  of 5 Italian local health units  distributed throughout 
the national territory with a population of health-assisted 
individuals of approximately 3.3 millions.
The following archives were used:
•	 the Health-assisted Subject Database, containing patients’ 
demographic data (year of birth and sex);
•	 the Medication Prescription Database, with all the infor-
mation for each medication prescribed, such as the ana-
tomical–therapeutic–chemical (ATC) code of the drug, 
the number of packs, the number of units per pack, the 
dosage, the unit cost per pack, and the prescription date;
•	 the Hospital Discharge Database, containing information 
on discharge for each hospitalization, in particular, dates 
of admission and discharge, and main and accessory 
diagnoses, coded according to the ICD, IX Revision, 
Clinical Modification (ICD-9-CM);
•	 the Specialized Outpatient Healthcare, recording the 
specialist services (visits, laboratory tests, diagnostic 
tests) given to the patients under reimbursement from 
the NHS;
•	 the Disease Exemption Database, which contains all 
ICD-9-CM codes relative to the disease exemptions for 
the subjects under investigation; from this database, all 
the information useful for diagnosis and/or comorbidities 
(to be integrated with those coming from hospitalization 
and drug consumption) were derived.
According to Italian privacy policy (D. lgs. 196/03 and 
subsequent modifications), each patient was assigned an 
anonymous code, which was not disclosed to the researchers. 
The anonymous code for each subject was present in all the 
databases and allowed the linkage between them. Accord-
ing to the policy governing the conduction of retrospective 
observational studies,12 the local ethical committee of each 
participating local health unit was notified of this study and 
accepted it. A preliminary version of this paper has been 
published as a journal supplement in Italian.13
Cohort definition
All the patients aged ≥18 years with at least 1 prescription 
for a biological drug for PSO or PsA from January 1, 2010 
to December 31, 2013, were included in the study. During 
the inclusion period, the date of the first biological prescrip-
tion was considered as the index date. All patients were 
observed for 12 months from the index date (observational 
follow-up period) and clinically characterized in the 12 
months preceding the index date (clinical characterization 
period). Only patients with biologic drug prescription were 
considered for this analysis. The diagnosis of PSO or PsA 
was identified through hospitalizations, exemption codes for 
PSO [code ICD-9 =69601 or exemption code 045.696.0] or 
PsA [code ICD-9 =696.0 or exemption code 045.696.1], and 
the medical prescriptions of anti-PSO drugs for topical use 
[ATC code = D050A].
For the analysis, the biological drugs listed in Table 1 
were considered.
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Patients were defined as “naïve” to biological treatment 
if they had not received a prescription for these drugs in 
the 12 months before the index date. Patients were defined 
“established” to biological treatments if they had at least 1 
prescription in the characterization period (biologic-experi-
enced). Only naïve patients were considered in the present 
investigation.
Prescription of conventional systemic drugs (including 
methotrexate [ATC codes = L01BA01, L04AX03], cyclo-
sporine [ATC codes = L04AD01, S01XA18], acitretin [ATC 
code = D05BB02] for patients with PSO, and methotrexate 
[ATC codes = L01BA01, L04AX03], leflunomide [ATC 
code = L04AA13], cyclosporine [ATC codes = L04AD01, 
S01XA18], sulfasalazine [ATC code = A07EC01] for patients 
with PsA) during the characterization period was also con-
sidered for the analysis.
Patients were classified according to the therapeutic 
strategy at the index date; in addition, all the patients were 
classified for sex, age, and on the basis of the Charlson 
Comorbidity Index (CCI),14 which assigns a weighted score 
to each concomitant diseases (if none, CCI is null).
Patients with a concomitant diagnosis of rheumatoid 
arthritis (ICD-9-CM code =	714 or exemption code 006), 
ankylosing spondylitis (ICD-9-CM code =	720.0 or exemp-
tion code 054), and Crohn’s disease (ICD-9-CM code =	555 
or exemption code 009) were excluded from the study.
Diagnostic procedures, principal and ancillary, during 
hospitalization were identified from the Hospital Discharge 
Database and classified according to procedure codes.
cost analysis
The cost analysis was conducted from the perspective of the 
Italian NHS. Costs are reported in Euros (€). Drug costs were 
evaluated using the Italian NHS purchase price, according 
to the year they were purchased. The costs deduced from the 
analyzed databases were classified as related or not related to 
the pathologies under evaluation, by using ICD-9-CM code 
696. The analysis focused on direct costs, which included 
expenses related to drug treatments, diagnostic evaluation, 
and hospitalizations during the characterization and follow-
up periods.
For the treatments, the package cost at the time of pur-
chase was considered; the costs for the outpatient services 
were taken from the regional price list, and the hospitaliza-
tion costs were derived directly from the Diagnosis-Related 
Group. The hospitalization cost could increase if the hospital-
ization exceeded the values assigned for a single Diagnosis-
Related Group.
statistical analysis
All the data are expressed as mean ± SD for continuous 
variables, while categorical variables are reported as percent-
ages. For each group, univariate analysis (χ2 test) was used 
to compare diagnostic procedures during characterization 
and follow-up period. All the analyses were performed using 
SPSS Windows version 18.0 (SPSS Inc., Chicago, IL, USA).
Results
A total of 351 patients with PSO or PsA, age ≥18 years, and 
naïve for biological drugs were included (Figure 1). Of these, 
214 (61%) were male, and the mean ± SD age was 50.3±13.7 
years. As for comorbidity, 26% of patients had a CCI score 
>0. Table 2 reports the demographic characteristics of the 
patients entering the study stratified according to the diag-
nosis of PSO or PsA. At the index date, the most commonly 
used drugs were etanercept (41% and 34% of patients with 
PSO and PsA, respectively) and adalimumab (35% vs 40%), 
followed by ustekinumab (19% vs 3%), golimumab (2% vs 
16%), and infliximab (3% vs 8%).
Among patients naïve to biological drugs during the 
characterization period who were later prescribed a biologi-
cal therapy, more than 50% with PSO and more than 80% 
with PsA had previously used a conventional systemic drug. 
Following initiation of biological drugs, the consumption 
of conventional systemic drugs decreased in both cohorts 
of patients, and approximately 1/3 of patients with PSO 
and 1/5 of patients with PsA were treated with biological 
monotherapy.
The most prescribed concomitant drugs nonrelated to 
PSO /PsA during the characterization period, in both PSO 
and PsA cohorts, were antibiotics for systemic use (ATC 
code = J01, mainly amoxicillin) and drugs used for acidosis-
related diseases (ATC code = A02, mainly omeprazole), with 
minor use during the follow-up period. Figure 2 reports 
the distribution of the diagnostic procedures, principal and 
ancillary, performed during the characterization and follow-
Table 1 Biological drugs and related aTc codes
Biological drugs ATC codes
adalimumab l04aB04
etanercept l04aB04
Infliximab l04aB02
Ustekinumab l04ac05
golimumab l04aB06
Abbreviation: aTc, anatomical–therapeutic–chemical.
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up periods. The incidence of hospitalization, mostly in day 
hospital regimen, decreased after the start of biological drug 
treatment, both in patients with PSO (from 12.3% to 3.2% 
in day hospital regimen [outpatient service] and from 2.4% 
to 0.4% in conventional hospital admission) and in patients 
with PsA (from 11.1% to 8.1% in day hospital regimen and 
from 10.1% to 3.0% in conventional hospital admission) 
(Figure 3). The major causes for hospitalization were PSO 
-/PsA-associated disorders (code ICD-9-CM =696 [PSO and 
similar disorders]) and cardiometabolic disorders (code ICD-
9-CM =401 [essential hypertension], 250 [diabetes mellitus], 
and 278 [overweight, obesity, and other hyperalimentation]). 
Patients with diagnosis of PsA had a greater number and a 
longer duration of hospitalizations (Figure 3). A detailed 
analysis on the incidence of hospitalization per quarter shows 
that the consumption of these resources was concentrated 
in the first quarter preceding the beginning of biological 
treatment, where 15% of the patients had a hospitalization 
admission (Figure 4).
As a consequence, the rate of consumption of health 
resources observed during the characterization and follow-up 
periods also impacts the annual cost of treatment per patient 
with PSO or PsA. Excluding the drug costs relative to the use 
of biological drugs (accounting for approximately €13,135 
and €12,606 for patients with PSO and PsA, respectively), the 
major differences in terms of costs are due to hospitalizations 
related to PSO /PsA (Figure 5). In the first 3 months prior to 
the index date, the mean annual cost relative to hospitalization 
was €217 for patients with PSO and €537 for patients with 
PsA. During the follow-up period, the mean annual cost for the 
use of concomitant drugs was slightly increased compared to 
the characterization period (from €249.8 to €269.4 for PSO 
and from €331.8 to €346.9 for PsA).
Figure 1 Flow chart of the study.
Abbreviations: PsO, psoriasis; Psa, psoriatic arthritis.
Health assisted population
3,300,000
Treated with biological drugs:
2,080 (6/10,000)
With diagnosis of psoriasis or PsA:
631 (2/10,000)
With diagnosis of psoriasis or PsA, 
naïve to biological drugs treatment:
351 (1.1/10,000)
Excluded: patients established to 
biological drugs treatment
Excluded: patients with concomitant 
diagnosis of rheumatoid arthritis, 
ankylosing spondylitis or Crohn’s disease
Table 2 characteristics of patients with PsO or Psa analyzed 
in the study
 Overall Psoriasis PsA
n 351 252 99
age (mean ± sD) 50.3±13.7 49.7±14.4 51.8±11.9
Male, n (%) 214 (61) 160 (63) 54 (55)
cci (mean ± sD) 0.4±1.0 0.4±1.0 0.4±1.0
cci >0, n (%) 93 (26) 70 (28) 23 (23)
Abbreviations: PsO, psoriasis; Psa, psoriatic arthritis; cci, charlson comorbidity 
Index.
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Figure 2 Diagnostic procedures, principal and ancillary, performed during the characterization and follow-up periods in patients with PsO (A) and Psa (B) naïve to biological 
drug treatment.
Abbreviations: PsO, psoriasis; Psa, psoriatic arthritis.
%
 o
f p
at
ie
nt
s
25
20
15
10
5
0
0.5Mean of LOS, days
PSO per
(252 patients)
PSO post
(252 patients)
PSA pre
(99 patients)
PSA post
(99 patients)
Conventional
Day hospital
Mean of LOS (hospitalization
per patient), days 3.5
0.1 1.3
6.32.2
0.5
4.3
Figure 3 hospitalization (conventional or day hospital) during the characterization and follow-up periods in patients with PsO and Psa naïve to biological drug treatment.
Abbreviations: PSO, psoriasis; PsA, psoriatic arthritis; pre, characterization period (12 months before the index date); post, follow-up period (12 months after the index 
date); lOs, length of stay (days).
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Discussion
The present study evaluated the therapeutic management 
and health resources consumption in patients with PSO /PsA 
before and after treatment with biological therapies in a real-
life clinical setting. In the last 20 years, treatment options for 
PSO and PsA have greatly improved. The biological therapies 
are able to interfere in a highly selective way, at different 
levels, and with different mechanisms of actions, targeting 
the immunological processes that trigger and maintain PSO 
and PsA. According to Italian guidelines for the prescription 
under NHS reimbursement regimen, relative to the time frame 
analyzed here, biological drugs are indicated for patients with 
PSO and/or PsA in the presence of severe clinical conditions 
and when conventional therapy cannot be administered.
Therefore, regardless of the recommendations relative to 
the starting of a biological therapy, our study seems to high-
light a tendency to underuse conventional systemic therapy 
in patients with PSO before the beginning of treatments with 
biological drugs. However, this result should be confirmed 
and further investigated since we did not take into account 
either the duration of treatment or the number of previous 
conventional systemic treatments before the prescription of 
a biological drug. In addition, the underuse of conventional 
systemic therapy may be likely related to the presence of 
contraindications to the treatment or to preexisting comor-
bidities in patients under investigation. Indeed, patients with 
PSO or PsA have a higher incidence of cardiometabolic 
comorbidities including obesity, hypertension, diabetes, 
dyslipidemia, and nonalcoholic fatty liver disease, which 
represent important limitations or contraindications to the 
use of cyclosporine, methotrexate, or acitretin.15,16
Our data are in line with recently published National 
Report on the drug use in Italy.17 The data on drug con-
sumption in the general population in Italy presented in 
the National Observatory on Drug Consumption (OsMed) 
2015 report show that the percentage of patients affected by 
PSO initiated on biological treatment without previous use 
of methotrexate or cyclosporine for at least 3 months was 
77.3%, a higher percentage than the previous year (+11.5%).
Actually, little information is available on the resources 
use and costs associated with the treatment of PSO and 
PsA in real clinical practice in Italy.18–21 From our analysis, 
it appears that there is a strong increment in the number of 
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Figure 4 Hospitalization trends stratified for quarter in patients with PSO and PsA 
naïve to biological drug treatment during the characterization and follow-up periods.
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Figure 5 health resources consumption and costs in patients with PsO and Psa naïve to biological drug treatment during the characterization and follow-up periods.
Notes: Conventional systemic drugs for PSO: methotrexate (ATC codes = l01Ba01, l04aX03), cyclosporine (aTc codes = l04aD01, s01Xa18), and acitretin (aTc 
code = D05BB02). Conventional systemic drugs for PsA: methotrexate (ATC codes = L01BA01, L04AX03), leflunomide (ATC code = l04aa13), cyclosporine (aTc codes 
= l04aD01, s01Xa18), and sulfasalazine (aTc code = A07EC01). Pre, characterization period (12 months before the index date); post, follow-up period (12 months after 
the index date). PSO patients: 252; PsA patients: 99.
Abbreviations: PsO, psoriasis; Psa, psoriatic arthritis; aTc, anatomical–therapeutic–chemical. 
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hospitalizations in the quarter preceding the beginning of 
anti-TNF-α therapy. It has to be noted that the majority of 
hospitalizations associated with PSO /PsA were in the day 
hospital regimen rather than conventional admissions. It 
could be reasoned that the services, performed both as day 
hospital and conventional admission to determine the eligibil-
ity of the patient to start a biological-based therapy, could be 
given in a different setting, with less use of NHS resources 
and similar benefit for the patients (albeit with a possible 
increase in indirect costs in charge to patients themselves). 
However, the increase in hospitalization could be due in part 
to the necessity to have a global evaluation of the patient with 
serious PSO or PsA. The results of our study, highlighting a 
reduction in the consumption of health resources, in terms of 
hospitalization, day hospital services, diagnostic procedures, 
and specialist outpatient care, following the beginning of a 
biological treatment are in accordance with previous Italian 
results by Spandonaro et al.20
The economic considerations based on real-world evi-
dence are an integral part of the optimization of the use of 
health resources and specific strategic recommendations 
for the management of the disease. In a global scenario of 
limited resources, the analysis of drugs and health resource 
consumption in the real clinical practice represents an 
important contribution to health professionals to increase 
the quality of the distribution process of economic resources 
and to guarantee equal access to the innovative therapeutic 
options based on clinical needs.
The data presented here have some limitations. It was 
not possible to associate a specific level of severity of the 
pathologies under investigation to patients; this information 
was missing in the databases due to their administrative 
nature. Consequently, the analysis could suffer from a bias 
selection of the patients. In addition, our analyses did not 
include all the costs associated with PSO treatment, and 
sensitivity analysis was not performed on our cohort. How-
ever, the study has the strength of being based on “real-life” 
data conducted in a limited but representative number of 
health care units. 
Conclusion
The results of our study suggest that  in PSO and PsA health 
resources utilization is mostly related to hospitalization; this 
consumption seems to peak during the quarter before the 
beginning of biologics therapies, and subsequently decreases 
after biologics initiation.
The findings are important as they can be used to opti-
mize the resources used by NHS. A better knowledge of 
prescription scheme and economic burden of a disease could 
stimulate the rational development of health programs aimed 
at potentiating services for its treatment.
Limitations
The study does not take into account the severity of PSO 
and PsA, as these data were not included in the databases. 
The study focuses on direct costs and does not include all 
the health costs related to PSO and PsA treatment. This is 
a real-life study conducted in a limited but representative 
number of Italian health care units.
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